Company news
Kezar Life Sciences, Inc. news in 2021
Kezar Life Sciences, Inc.'s news releases, calls and decks from 2021, newest first.
Kezar Appoints Courtney Wallace to its Board of Directors
December 9, 2021
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
November 14, 2021
Kezar Reports Third Quarter Financial Results and Provides Business Update
November 8, 2021
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
November 2, 2021
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
October 26, 2021
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
October 4, 2021
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
August 22, 2021
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
August 11, 2021
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
June 7, 2021
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
June 1, 2021
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
May 31, 2021
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates
May 11, 2021
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting
April 9, 2021
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates
March 10, 2021
Decks in 2021
- Investor Day (November 2021)
Investor day · 62 slides · Nov 15, 2021